Weight-loss drug targets fat that endangers heart According to a study published by UTSW preventive cardiologist Parag Joshi, M.D., a once-daily dose of liraglutide combined with lifestyle interventions significantly lowered two types of fat that endanger heart health
GLP-1 (glucagon-like peptide-1) is a hormone that helps regulate appetite and food intake
In some cases, people have received compounded GLP-1s labeled to come from pharmacies that didnt actually compound the drug or seemingly dont even exist
People on GLP-1 drugs stop wanting filling foods first, so protein crashes harder than carbs or fat in the average patients intake log
Regarding the secondary endpoint of the proportion of patients achieving 20% body weight reduction within the study, there was a dose-dependent group size of 50% of the participants receiving the dose of 10 mg tirzepatide and a proportion of 57% in the study arm with 15 mg
The satiety-inducing effects of GLP-1 RAs, combined with their ability to address hyperglycemia, make them a valuable tool for managing obesity and metabolic disorders
